"A product launch in the Rest of World requires western clinical studies (in addition to the Japanese trials) and the feasibility of Biota taking the product further into this process to capture greater value is well in hand."
The use of the word 'feasibility' concerns me, as it portrays very initial/early thoughts of a desire to take Inavir to Phase 111 in US, whereas the Chairmans address at the AGM was more positive - 3 to 6 months, done an dusted.
I would have used 'program' ie something is in place to progress phase 111.
BTA Price at posting:
$1.30 Sentiment: Buy Disclosure: Held
